INOMAX is indicated for the treatment of Hypoxic Respiratory Failure (HRF) in term and near-term infants |
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
INOMAX Important Safety Information (ISI)
INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
About INOMAX
INOMAX has been shown to provide:
In addition to INOMAX (nitic oxide) for inhalation, you get all the critical drug delivery systems required for INOMAX administration including:
 INOmax DS developed for bedside or transport situations. It meets all FDA specifications for INOMAX drug delivery. |
 INOvent a bedside delivery system for INOMAX. It meets all of the FDA-required specifications for INOMAX drug delivery systems. |
To learn more or to schedule an appointment with one of your INOMAX representatives, medical science liaisons, or service technicians, please call 1-877-566-9466. For additional information, please Contact Us.
References
5. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336:597-604.
7. INOMAX® [package insert]. Clinton, NJ: Ikaria Holdings; 2009.
8. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. Pediatrics. 1998;101:325-334.
9. Data on file. Clinton, NJ: Ikaria®; 2009.
9. Data on file. Clinton, NJ: Ikaria®; 2009.